- Home
- Clinical Trials
- Combined Immunotherapy and Chemotherapy for Muscle-invasive Bladder Cancer
Combined Immunotherapy and Chemotherapy for Muscle-invasive Bladder Cancer
- Trial ID:
- IRB-19-7391
- Munveer S Bhangoo, MD
Inclusion Criteria
- Be 18 years of age or older
- Have a confirmed diagnosis of Muscle – invasive Bladder Cancer (MIBC), Clinical Stage T2-T4aN0M0
- Must be eligible to receive cisplatin chemotherapy.
- Be eligible for surgical treatment and agree to planned surgical treatment
Exclusion Criteria
- Have received any prior systemic anti-cancer treatment for MIBC
- Be pregnant or breastfeeding or expecting to conceive or father children within the defined study duration
- Have a known history of HIV, Hepatitis B, or active Hepatitis C
Additional Info
- All patients will receive chemotherapy (cisplatin + gemcitabine) and surgery and will be randomly selected to receive either pembrolizumab or placebo.
- All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines. Study treatment will occur for approximately 1 year and patients will be followed for up to 5 years after treatment has ended.
- For more information, search for NCT03924856 at www.clinicaltrials.gov
Contact Info:
- Gail Moore
- Moore.Gail@scrippshealth.org
- 858-554-8365